Related references
Note: Only part of the references are listed.Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer
Francois M. Lemoine et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2009)
Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma
D. S. Green et al.
BRITISH JOURNAL OF DERMATOLOGY (2008)
Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers
Antoun Toubaji et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
T regulatory type 1 cells in squamous cell carcinoma of the head and neck: Mechanisms of suppression and expansion in advanced disease
Christoph Bergmann et al.
CLINICAL CANCER RESEARCH (2008)
Development of multi-epitope vaccines targeting wild-type-sequence p53 peptides
Albert B. DeLeo et al.
EXPERT REVIEW OF VACCINES (2008)
Immunosuppression induced by immature dendritic cells is mediated by TGF-β/IL-10 double-positive CD4+ regulatory T cells
N. Cools et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2008)
The frequency and suppressor function of CD4+CD25high Foxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck
Laura Strauss et al.
CLINICAL CANCER RESEARCH (2007)
Toward the development of multi-epitope p53 cancer vaccines:: An in vitro assessment of CD8+ T cell responses to HLA class I-restricted wild-type sequence p53 peptides
Koichi Sakakura et al.
CLINICAL IMMUNOLOGY (2007)
Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers
Inge Marie Svane et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection
Antoun Toubaji et al.
VACCINE (2007)
DC-based cancer vaccines
Eli Gilboa
JOURNAL OF CLINICAL INVESTIGATION (2007)
Peptide vaccination of patients with metastatic melanoma - Improved clinical outcome in patients demonstrating effective immunization
Svetomir N. Markovic et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2006)
Combined prophylactic and therapeutic cancer vaccine: Enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice
JH Qian et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests
W. J. Lesterhuis et al.
ANNALS OF ONCOLOGY (2006)
Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma:: a randomized phase III trial of the DC study group of the DeCOG
D Schadendorf et al.
ANNALS OF ONCOLOGY (2006)
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells
J Dannull et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy
IJM de Vries et al.
NATURE BIOTECHNOLOGY (2005)
Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer
Z Su et al.
JOURNAL OF IMMUNOLOGY (2005)
Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma
M Lotem et al.
BRITISH JOURNAL OF CANCER (2004)
Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study
IM Svane et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Therapeutic dendritic-cell vaccine for chronic HIV-1 infection
W Lu et al.
NATURE MEDICINE (2004)
Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule
CL Slingluff et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients
I Bedrosian et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells
T Maier et al.
BLOOD (2003)
Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens
GQ Phan et al.
JOURNAL OF IMMUNOTHERAPY (2003)
The use of dendritic cells in cancer immunotherapy
G Schuler et al.
CURRENT OPINION IN IMMUNOLOGY (2003)
Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected stage II melanoma
J Weber et al.
CANCER (2003)
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells
CL Slingluff et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection
H Jonuleit et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Dendritic cells in transplantation - Friend or foe?
R Lechler et al.
IMMUNITY (2001)
Clinical trial designs for the early clinical development of therapeutic cancer vaccines
RM Simon et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells
MV Dhodapkar et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Share Paper
